Evergreen Talk Series: Clinical Benefits of Linagliptin and Dapagliflozin Combination in Type 2 Diabetes Management

Written By :  Dr. Brij Mohan Makkar
Written By :  Dr Sameer I. Dani
Written By :  Dr Tukaram Jamale
Written By :  MD Brand Connect
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2023-11-10 06:24 GMT   |   Update On 2024-03-18 10:37 GMT
Advertisement

Presenting the Evergreen Talk Series featuring Dr. Brij Mohan Makkar, a Senior Diabetologist and Obesity Specialist from Delhi, Dr. Sameer I. Dani, an Interventional Cardiologist from Ahmedabad, and Dr. Tukaram Jamale, a Nephrologist and Kidney Transplant Physician who serves as the Head of the Department at KEM Hospital Mumbai. They provide their insights on the use of Linagliptin, Dapagliflozin, and Metformin for diabetic patients.

Advertisement

Bringing viewpoints from the different specialities of Diabetology, Cardiology and Nephrology they share the clinical benefits of the Linagliptin and Dapagliflozin combination in Type 2 Diabetes management.

Dr Brij Mohan Makkar: Both are important OADs; the mechanisms that contribute to the development of hyperglycemia and increased blood glucose level that are targeted by these two molecules are actually different mechanisms, so they have good complementary action. They provide a good synergy as far as the treatment of diabetes is concerned. Both these drugs help control glycemia, and at the same time, they reduce the risk of complications; that is why they provide a very good synergy, and they can be an Evergreen combination for treating people with T2DM.

Dr Sameer I Dani: For Asians and Indians, especially those who are considered thin fat people as far as the CV risk category goes, these drugs in combination will probably offer maximum CV benefits to diabetic patients. It is not only the intensive glycemic control that is important; it is very important to show that you have improved cardiovascular outcomes in a diabetic patient.


Dr Tukaram Jamale: With regards to kidney protection due to diabetic kidney disease, dapagliflozin is best supported by the evidence both in patients with diabetes and even in non-diabetic chronic kidney disease. Linagliptin can offer the best of the two worlds. One is the Glycemic control, and the other is organ protection. So, this would definitely make a case for this combination to be used.

.post-meta, .post-meta a{display:none !important;} #index-1-ad-before, #index-2-ad-before, #index-3-ad-before, #inside_post_content_ad_2_before{min-height: 0px !important;}#inside_post_content_ad_1{display:none !important;} #inside_post_content_ad_2{display:none!important; }
Full View
Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News